Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Initumab + pyrotinib + toripalimab for HER2-variant advanced solid tumors
ChiCTR2400089182Phase 2Not yet recruiting
- Sponsor
- Shanghai East Hospital
- Start
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of initumab, pyrotinib and toripalimab in Nonhematologic neoplasms, sponsored by Shanghai East Hospital. Primary endpoint: Objective Response Rate. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
initumabpyrotinibtoripalimab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2400089182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089182.